Convergence of atherosclerosis and Alzheimer's disease: Inflammation, cholesterol, and misfolded proteins

Lancet

Volumn 363, Issue 9415, 2004, Pages 1139-1146

  Casserly, Ivan ^a   Topol, Eric ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; APOLIPOPROTEIN E4; BLOOD CLOTTING FACTOR; CHEMOKINE; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER; COMPLEMENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENZYME; GROWTH FACTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGENASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PRAVASTATIN; PYRIDINE DERIVATIVE;

ALZHEIMER DISEASE; ANGIOGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRAIN ATHEROSCLEROSIS; BRAIN ISCHEMIA; BRAIN MICROCIRCULATION; BRAIN REGION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DEVELOPING COUNTRY; DIABETES MELLITUS; DISEASE COURSE; DNA POLYMORPHISM; DRUG EFFECT; ENVIRONMENTAL FACTOR; EPIDEMIOLOGICAL DATA; FAT INTAKE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INFLAMMATION; LONG TERM CARE; MEDIATOR RELEASE; METABOLIC SYNDROME X; NEUROFIBRILLARY TANGLE; NONHUMAN; OBESITY; ONSET AGE; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FOLDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SENILE PLAQUE; THROMBOCYTE; TREATMENT OUTCOME;

EID: 1842528400     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15900-X     Document Type: Review

References (103)

1. Cummings J.L., Cole G. Alzheimer disease. JAMA. 287:2002;2335-2338.
2. Minino A.M., Arias E., Kochanek K.D., Murphy S.L., Smith B.L. Deaths: final data for 2000. Natl Vital Stat Rep. 50:2002;1-119.
3. Collen M.F. Vicissitudes of preventive medicine and a new challenge. Methods Inf Med. 41:2002;224-229.
4. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 88:1998;1337-1342.
5. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 81:2001;741-766.
6. Ritchie K., Lovestone S. The dementias. Lancet. 360:2002;1759-1766.
7. Hofman A., Ott A., Breteler M.M., et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet. 349:1997;151-154.
8. Roher A.E., Esh C., Kokjohn T.A., et al. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol. 23:2003;2055-2062.
9. de la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke. 33:2002;1152-1162.
10. Vermeer S.E., Prins N.D., den Heijer T., Hofman A., Koudstaal P.J., Breteler M.M. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 348:2003;1215-1222.
11. Farkas E., Luiten P.G. Cerebral microvascular pathology in aging and Alzheimer's disease. Prog Neurobiol. 64:2001;575-611.
12. Tuzcu E.M., Kapadia S.R., Tutar E., et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 103:2001;2705-2710.
13. Ohm T.G., Muller H., Braak H., Bohl J. Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes. Neuroscience. 64:1995;209-217.
14. Sparks D.L., Hunsaker J.C., Scheff S.W., Kryscio R.J., Henson J.L., Markesbery W.R. Cortical senile plaques in coronary artery disease, aging and Alzheimer's disease. Neurobiol Aging. 11:1990;601-607.
15. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med. 8:2002;1211-1217.
16. Steinberg D. The cholesterol controversy is over. Why did it take so long? Circulation. 80:1989;1070-1108.
17. Notkola I.L., Sulkava R., Pekkanen J., et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology. 17:1998;14-20.
18. Frears E.R., Stephens D.J., Walters C.E., Davies H., Austen B.M. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport. 10:1999;1699-1705.
19. Simons M., Keller P., De Strooper B., Beyreuther K., Dotti C.G., Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA. 95:1998;6460-6464.
20. Refolo L.M., Malester B., LaFrancois J., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 7:2000;321-331.
21. Papassotiropoulos A., Streffer J.R., Tsolaki M., et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol. 60:2003;29-35.
22. Puglielli L., Konopka G., Pack-Chung E., et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol. 3:2001;905-912.
23. Kusunoki J., Hansoty D.K., Aragane K., Fallon J.T., Badimon J.J., Fisher E.A. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 103:2001;2604-2609.
24. Rodriguez A., Usher D.C. Anti-atherogenic effects of the acyl-CoA:cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages. Atherosclerosis. 161:2002;45-54.
25. Kojro E., Gimpl G., Lammich S., Marz W., Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase Alzheimer's disease AM 10. Proc Natl Acad Sci USA. 98:2001;5815-5820.
26. Hansson G.K., Libby P., Schonbeck U., Yan Z.Q. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 91:2002;281-291.
27. Akiyama H., Barger S., Barnum S., et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 21:2000;383-421.
28. Witztum J.L., Berliner J.A. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol. 9:1998;441-448.
29. Wyss-Coray T., Yan F., Lin A.H., et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci USA. 99:2002;10837-10842.
30. Gehrmann J., Matsumoto Y., Kreutzberg G.W. Microglia: intrinsic immuneffector cell of the brain. Brain Res Brain Res Rev. 20:1995;269-287.
31. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Brain Res Rev. 21:1995;195-218.
32. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 887:2000;80-89.
33. Cagnin A., Brooks D.J., Kennedy A.M., et al. In-vivo measurement of activated microglia in dementia. Lancet. 358:2001;461-467.
34. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol. 52:2002;168-174.
35. Wilson P.W., Schaefer E.J., Larson M.G., Ordovas J.M. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 16:1996;1250-1255.
36. Farrer L.A., Cupples L.A., Haines J.L., et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease, A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 278:1997;1349-1356.
37. Lehtimaki T., Moilanen T., Viikari J., et al. Apolipoprotein E phenotypes in Finnish youths: a cross-sectional and 6-year follow-up study. J Lipid Res. 31:1990;487-495.
38. Boyles J.K., Pitas R.E., Wilson E., Mahley R.W., Taylor J.M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 76:1985;1501-1513.
39. Huang Z.H., Mazzone T. ApoE-dependent sterol efflux from macrophages is modulated by scavenger receptor class B type I expression. J Lipid Res. 43:2002;375-382.
40. Michikawa M., Fan Q.W., Isobe I., Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem. 74:2000;1008-1016.
41. Miyata M., Smith J.D. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 14:1996;55-61.
42. Brasier A.R., Recinos A., Eledrisi M.S. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 22:2002;1257-1266.
43. Savaskan E., Hock C., Olivieri G., et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging. 22:2001;541-546.
44. MacGregor D.P., Murone C., Song K., Allen A.M., Paxinos G., Mendelsohn F.A. Angiotensin II receptor subtypes in the human central nervous system. Brain Res. 675:1995;231-240.
45. Hirawa N., Uehara Y., Kawabata Y., et al. Long-term inhibition of renin-angiotensin system sustains memory function in aged Dahl rats. Hypertension. 34:1999;496-502.
46. Barnes J.M., Barnes N.M., Costall B., et al. Angiotensin II inhibits cortical cholinergic function: implications for cognition. J Cardiovasc Pharmacol. 16:1990;234-238.
47. Hu J., Igarashi A., Kamata M., Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem. 276:2001;47863-47868.
48. Haass C., Schlossmacher M.G., Hung A.Y., et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature. 359:1992;322-325.
49. Chen M., Inestrosa N.C., Ross G.S., Fernandez H.L. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun. 213:1995;96-103.
50. De Meyer G.R., De Cleen D.M., Cooper S., et al. Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res. 90:2002;1197-1204.
51. Skovronsky D.M., Lee V.M., Pratico D. Amyloid precursor protein and amyloid beta peptide in human platelets. Role of cyclooxygenase and protein kinase C. J Biol Chem. 276:2001;17036-17043.
52. Santiago-Garcia J., Mas-Oliva J., Innerarity T.L., Pitas R.E. Secreted forms of the amyloid-beta precursor protein are ligands for the class A scavenger receptor. J Biol Chem. 276:2001;30655-30661.
53. Tedgui A., Mallat Z. Platelets in atherosclerosis: a new role for beta-amyloid peptide beyond Alzheimer's disease. Circ Res. 90:2002;1145-1146.
54. Freeman M.W., Moore K.J. eLiXiRs for restraining inflammation. Nat Med. 9:2003;168-169.
55. Wang L., Schuster G.U., Hultenby K., Zhang Q., Andersson S., Gustafsson J.A. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci USA. 99:2002;13878-13883.
56. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 9:2003;213-219.
57. Schuster G.U., Parini P., Wang L., et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation. 106:2002;1147-1153.
58. Tangirala R.K., Bischoff E.D., Joseph S.B., et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci USA. 99:2002;11896-118901.
59. Bucciarelli L.G., Wendt T., Rong L., et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci. 59:2002;1117-1128.
60. Schleicher E.D., Wagner E., Nerlich A.G. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 99:1997;457-468.
61. Hofmann M.A., Drury S., Fu C., et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 97:1999;889-901.
62. Park L., Raman K.G., Lee K.J., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med. 4:1998;1025-1031.
63. Yan S.D., Chen X., Fu J., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature. 382:1996;685-691.
64. Vitek M.P., Bhattacharya K., Glendening J.M., et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA. 91:1994;4766-4770.
65. Sueishi K., Yonemitsu Y., Nakagawa K., Kaneda Y., Kumamoto M., Nakashima Y. Atherosclerosis and angiogenesis Its pathophysiological significance in humans as well as in an animal model induced by the gene transfer of vascular endothelial growth factor. Ann N Y Acad Sci. 811:1997;311-324.
66. Zhang Y., Cliff W.J., Schoefl G.I., Higgins G. Immunohistochemical study of intimal microvessels in coronary atherosclerosis. Am J Pathol. 143:1993;164-172.
67. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:1992;843-845.
68. Vasse M., Pourtau J., Trochon V., et al. Oncostatin M induces angiogenesis in vitro and in vivo. Arterioscler Thromb Vasc Biol. 19:1999;1835-1842.
69. Celletti F.L., Waugh J.M., Amabile P.G., Brendolan A., Hilfiker P.R., Dake M.D. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 7:2001;425-429.
70. Moulton K.S., Heller E., Konerding M.A., Flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 99:1999;1726-1732.
71. Vagnucci A.H., Li W.W. Alzheimer's disease and angiogenesis. Lancet. 361:2003;605-608.
72. Kalaria R.N. The blood-brain barrier and cerebral microcirculation in Alzheimer disease. Cerebrovasc Brain Metab Rev. 4:1992;226-260.
73. Farkas E., De Jong G.I., de Vos R.A., Jansen Steur E.N., Luiten P.G. Pathological features of cerebral cortical capillaries are doubled in Alzheimer's disease and Parkinson's disease. Acta Neuropathol (Berl). 100:2000;395-402.
74. Grammas P., Moore P., Weigel P.H. Microvessels from Alzheimer's disease brains kill neurons in vitro. Am J Pathol. 154:1999;337-342.
75. Rhodin J.A., Thomas T. A vascular connection to Alzheimer's disease. Microcirculation. 8:2001;207-220.
76. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 101:2000;207-213.
77. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 21:2001;1712-1719.
78. Wolozin B., Kellman W., Ruosseau P., Celesia G.G., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 57:2000;1439-1443.
79. Jick H., Zornberg G.L., Jick S.S., Seshadri S., Drachman D.A. Statins and the risk of dementia. Lancet. 356:2000;1627-1631.
80. Rockwood K., Kirkland S., Hogan D.B., et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 59:2002;223-227.
81. Green R, Farrer LA. World Alzheimer Congress 2002, Stockholm.
82. Shepherd J., Blauw G.J., Murphy M.B., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 360:2002;1623-1630.
83. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
84. Fassbender K., Simons M., Bergmann C., et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci USA. 98:2001;5856-5861.
85. Delanty N., Vaughan C.J., Sheehy N. Statins and neuroprotection. Expert Opin Investig Drugs. 10:2001;1847-1853.
86. Vaughan C.J., Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 30:1999;1969-1973.
87. Amin-Hanjani S., Stagliano N.E., Yamada M., Huang P.L., Liao J.K., Moskowitz M.A. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 32:2001;980-986.
88. Pahan K., Sheikh F.G., Namboodiri A.M., Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophage. J Clin Invest. 100:1997;2671-2679.
89. Aisen P.S., Schafer K.A., Grundman M., et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 289:2003;2819-2826.
90. Etminan M., Gill S., Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 327:2003;128.
91. Yermakova A.V., Rollins J., Callahan L.M., Rogers J., O'Banion M.K. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol. 58:1999;1135-1146.
92. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res. 830:1999;226-236.
93. Weggen S., Eriksen J.L., Das P., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
94. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81-106.
95. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
96. Cyrus T., Sung S., Zhao L., Funk C.D., Tang S., Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 106:2002;1282-1287.
97. Pratico D., Tillmann C., Zhang Z.B., Li H., FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA. 98:2001;3358-3363.
98. Kivipelto M., Helkala E.L., Laakso M.P., et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ. 322:2001;1447-1451.
99. Seshadri S., Beiser A., Selhub J., et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 346:2002;476-483.
100. Ott A., Stolk R.P., van Harskamp F., Pols H.A., Hofman A., Breteler M.M. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology. 53:1999;1937-1942.
101. Kalmijn S., Foley D., White L., et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol. 20:2000;2255-2260.
102. Prince M., Cullen M., Mann A. Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial. Neurology. 44:1994;97-104.
103. Gustafson D., Rothenberg E., Blennow K., Steen B., Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med. 163:2003;1524-1528.